Surufatinib is a Small Molecule owned by Hutchison MediPharma, and is involved in 54 clinical trials, of which 17 were completed, 21 are ongoing, and 16 are planned.

Surufatinib is an anti cancer therapy. The drug candidate acts by inhibiting multiple kinases. It inhibits all three forms of vascular endothelial growth factor receptors (VEGFR-1,2,3). Epidermal growth factor attach to the receptor and activates the receptor. These pathways act in a coordinated manner to promote cell differentiation. The drug candidate also inhibits fibroblast growth factor receptor 1 (FGFR-1). Fibroblast growth factor (FGFs) binds to its receptor and activates it. Inhibition of the CSF-1R signaling pathway blocks the activation of tumor-associated macrophages, which are involved in suppressing immune responses against tumors.

The revenue for Surufatinib is expected to reach a total of $4.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Surufatinib NPV Report.

Surufatinib is originated and owned by Hutchison MediPharma. Hutchmed China is the other company associated in development or marketing of Surufatinib.

Surufatinib Overview

Surufatinib (Sulanda) is a potential antineoplastic and anti-angiogenic agent. It is formulated as capsules for oral route of administration. Sulanda is indicated for the treatment of non-pancreatic neuroendocrine tumors (“NETs”). Surufatinib is under development for the treatment of neuroendocrine tumors, solid tumors,  primary peritoneal cancer, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, lymphoma, non-rhabdomyosarcoma soft tissue sarcoma, neuroendocrine tumors of pancreatic and non-pancreatic (Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET)), thyroid and gallbladder cancer, non-small cell lung cancer, extrahepatic cholangiocarcinoma, medullary thyroid cancer, metastatic biliary tract carcinoma including extrahepatic cholangiocarcinoma (EHCC), endometrial cancer, colorectal cancer, neuroendocrine carcinoma, adenocarcinoma of the gastroesophageal junction, soft tissue sarcoma, small-cell lung cancer, gastric cancer, esophageal squamous cell carcinoma, intrahepatic cholangiocarcinoma (IHCC) or gallbladder biliary carcinoma (GBC), epithelial ovarian cancer and fallopian tube cancer. It is administered orally.

Hutchmed China Overview

Hutchmed China (Hutchmed) formerly known as Hutchison China MediTech is a biopharmaceutical company which discovers, develops, manufactures and commercializes drugs for the treatment of solid tumors and hematological malignancies; and immunological disorders. It also offers over-the-counter (OTC) pharmaceuticals and consumer healthcare products. Hutchmed also provides R&D services to other companies. It has a broad pipeline of drug candidates indicated for the treatment of immunological diseases, besides novel oral drug candidates for various cancers and inflammation. It operates in China, North America, Europe and Australia. The company offers prescription drugs to hospitals in China through direct sales force. It distributes consumer health products in China. Hutchmed is headquartered in Kowloon, Hong Kong.

The company reported revenues of (US Dollars) US$356.1 million for the fiscal year ended December 2021 (FY2021), an increase of 56.2% over FY2020. The operating loss of the company was US$207 million in FY2021, compared to an operating loss of US$196.7 million in FY2020. The net loss of the company was US$194.7 million in FY2021, compared to a net loss of US$125.7 million in FY2020.

Quick View – Surufatinib

Report Segments
  • Innovator (NME)
Drug Name
  • Surufatinib
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.